Dylan Barnett, MD
Family Medicine · Paragould, ARNPI 1073075735
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 110 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AstraZeneca at 24.4% of the total. 2025 is the largest year on record at $981, more than ten times the $74 reported in 2021.
Across 110 payments — averaging $20.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$561
- GSK$302
- Novo Nordisk$295
- AbbVie$179
- Boehringer Ingelheim$148
- Otsuka America Pharmaceutical, Inc.$144
- plus $672 from 17 others
What the payments were for
- Food & beverage$2,301100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 13 | $561 |
| GSK | 20 | $302 |
| Novo Nordisk | 16 | $295 |
| AbbVie | 14 | $179 |
| Boehringer Ingelheim | 5 | $148 |
| Otsuka America Pharmaceutical, Inc. | 6 | $144 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $133 |
| Lundbeck LLC | 3 | $83 |
| Pfizer | 4 | $81 |
| Astellas Pharma US Inc | 4 | $63 |
| Seqirus USA Inc | 2 | $55 |
| Medtronic | 2 | $41 |
| Bayer | 2 | $36 |
| Tris Pharma Inc | 2 | $35 |
| Sanofi | 1 | $24 |
| Lilly USA, LLC | 1 | $20 |
| Merck | 1 | $19 |
| Aimmune Therapeutics, Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Eisai Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $12 |
| Corium, LLC | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,301 in reported general payments places this provider in the 75th percentile of 1,347 family medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 151 | $139,755 |
| JardianceEmpagliflozin | 124 | $108,111 |
| MounjaroTirzepatide | 73 | $74,266 |
| EliquisApixaban | 81 | $67,502 |
| FarxigaDapagliflozin Propanediol | 80 | $63,575 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 85 | $57,168 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 69 | $48,745 |
| Humulin R U-500Insulin Regular, Human | 13 | $46,075 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 35 | $25,407 |
| LinzessLinaclotide | 35 | $24,407 |
| XareltoRivaroxaban | 18 | $19,435 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $16,344 |
| EntrestoSacubitril/Valsartan | 19 | $14,656 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $14,583 |
| Lurasidone Hcl | 13 | $12,732 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $295 | $139,755151 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat | $148 | $123,887151 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $561 | $112,320149 claims |
| Lilly USA, LLCMounjaro | $20 | $74,26673 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $302 | $72,795117 claims |
| PfizerEliquis | $81 | $67,50281 claims |
| MerckJanumet Xr, Janumet | $19 | $36,98750 claims |
| AbbVieLinzess | $179 | $24,40735 claims |
| Astellas Pharma US IncMyrbetriq | $63 | $7,65313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in Paragould
- Hetal PatelParagould$147K
- Clarence KempParagould$16K
- Vincent LeeParagould$16K
- Glenn GibbonsFort Smith$179K
- David GersonSherwood$119K
- Scott MusickBentonville$102K
- Broderick EatonWynne$49K
- Craig LevoyBentonville$30K
- Allen BeachyFort Smith$21K
- Hunter CarringtonHot Springs$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.